Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angioma
Pediatric Dermatology2018Vol. 35(5), pp. 635–638
Citations Over TimeTop 10% of 2018 papers
Abstract
Sirolimus as first-line therapy shows great promise in the treatment of kaposiform hemangioendothelioma and tufted angioma.
Related Papers
- → Oral and Topical Sirolimus for Vascular Anomalies: A Multicentre Study and Review(2019)54 cited
- → Lymphangioleiomyomatosis Treatment With Sirolimus(2011)16 cited
- Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection.(2000)
- Application of sirolimus in drug-eluting stent(2009)
- Pharmacokinetics of Sirolimus in Subjects Treated with Intravitreal Sirolimus in the SAVE-2 Study: Sirolimus As Therapeutic Approach to UVEitis – Protocol 2 with Two Doses of Intravitreal Sirolimus(2018)